Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Thyroid Diseases × Thyroxine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 7 Hypothyroidism 5 Thyroid Diseases 1 Sarcoma, Alveolar Soft Part 1 Recurrence 1 Postoperative Complications 1 Polycystic Ovary Syndrome 1 Neoplasms 1 Infertility, Female 1 Goiter 1 Fatigue 1 Depression 1 Anxiety Disorders 1 Advanced Differentiated Thyroid Gland Carcinoma 1

Interventions

selpercatinib 2 cabozantinib 2 Thyroid (USP) 2 Sorafenib 2 Sodium 2 Radiofrequency Ablation 2 Metformin 2 vandetanib 1 tomivosertib 1 temsirolimus 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 lenvatinib 1 apatinib 1 acetaminophen, codeine drug combination 1 Vitamin B 12 1 Tramadol 1 Thyroxine 1 Thyrotropin-Releasing Hormone 1 Technetium Tc 99m Sestamibi 1 Surgical Procedures, Operative 1 Pemetrexed 1 Panobinostat 1 Negative-Pressure Wound Therapy 1 NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt 1 Lysine Acetyltransferase 5 1 Iodine-131 1 Folic Acid 1 Fluorescein 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07239674 2025-11-20

DELTA

West China Hospital

Phase 3 Not yet recruiting

Thyroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡